Protective Effect of Anar-5 Herbal Treatment on Experimental Chronic Atrophic Gastritis in Wistar Rats
Abstract
Background: Chronic gastritis is a slowly progressive disease. It includes atrophy of gastric mucosa, impairment of epithelial regeneration, formation of lymphoid tissue/germinal center, loss of gastric secretion and movement. The Mongolian traditional medicine used Anar-5 recipes for the treatment of stomachache, emesis, and improvement of gastricdigestion. Based on these observations, we implemented a rat model of Anar-5 treatment in artificial chronic gastritis in order to elucidate its potential protective mechanisms scientifically.
Methods and material: We established an experimental rat model of chronic gastritis by use of ammonia water. We divided the rat cohorts in an Anar-5–treated test group, an untreated cohort, and a control group. The untreated group was fed with 0.1% ammonia water and the treated group with both 0.1% ammonia water and administered Anar-5 100 mg/kg/day for 6 weeks. Gastric lesions were evaluated microscopically. The Prostaglandin E2 levels, cyclooxygenase COX-2 expression and the cellular proliferation marker Ki67 were in addition assessed.
Results: The Anar-5 cohort displayed with an increased thickness of the antrum mucosa, number (р˂0.05) and regeneration zones of gastric mucous epithelial cells when compared to the results of the untreated cohort (693.1±63.8 μm versus 429.6±43.5 μm). The untreated cohort displayed with decreased PGE2 levels (14.8±0.62 ng/dl) when compared to those of the control group and Anar-5 cohort (19.5±1.22 ng/dl and 8.7+0.32 g/dl protein, respectively). The Ki67-associated proliferation rate of the antrum mucosa was enhanced and measured 19.75% in the untreated cohort in comparison to a proliferation rate of 6.58% in the Anar-5 cohort.
Conclusion: The data of our rat experiment indicate that a contemporary application of Anar-5 herbs acts as a gastric mucosal protective agent. In addition it induces an overexpression of COX-2 and maintenance of the PGE2 lev
Methods and material: We established an experimental rat model of chronic gastritis by use of ammonia water. We divided the rat cohorts in an Anar-5–treated test group, an untreated cohort, and a control group. The untreated group was fed with 0.1% ammonia water and the treated group with both 0.1% ammonia water and administered Anar-5 100 mg/kg/day for 6 weeks. Gastric lesions were evaluated microscopically. The Prostaglandin E2 levels, cyclooxygenase COX-2 expression and the cellular proliferation marker Ki67 were in addition assessed.
Results: The Anar-5 cohort displayed with an increased thickness of the antrum mucosa, number (р˂0.05) and regeneration zones of gastric mucous epithelial cells when compared to the results of the untreated cohort (693.1±63.8 μm versus 429.6±43.5 μm). The untreated cohort displayed with decreased PGE2 levels (14.8±0.62 ng/dl) when compared to those of the control group and Anar-5 cohort (19.5±1.22 ng/dl and 8.7+0.32 g/dl protein, respectively). The Ki67-associated proliferation rate of the antrum mucosa was enhanced and measured 19.75% in the untreated cohort in comparison to a proliferation rate of 6.58% in the Anar-5 cohort.
Conclusion: The data of our rat experiment indicate that a contemporary application of Anar-5 herbs acts as a gastric mucosal protective agent. In addition it induces an overexpression of COX-2 and maintenance of the PGE2 lev
Downloads
Download data is not yet available.
References
1. Enkhdolgor G, Bira N, Badamjav S. Digestive system diseases. Ulaanbaatar, 2009; 161-206, 424-427.
2. Ganchimeg U, Angarmurun D, Davaalham D. The current situation of the non-communicable disease in Mongolia. Mongolian journal of health sciences 2010; 1:7 .
3. Tumurbaatar N: Hot-Natured Disorders in Traditional Mongolian Medicine. 1998, Eruul enkh press, Ulaanbaatar
4. Manag rinchin junai: Traditional Medical source book. 1978, People's Republic of China: “Inner Mongolian medical treasurers†printing house, Ulaanbaatar
5. Ligaa U, Davaasuren B, Ninjil N: Mongolian Medicinal Plants Using in Western and Eastern Medicine. 2005, JKC printing, Ulaanbaatar
6. Myagmar BE, Aniya Y: Free radical scavenging action of medicinal herbs from Mongolia. Phytomedicine. 2000, 7: 221-9. 10.1016/S0944-7113(00)80007-0.
7. Takao Noguchi, Eiji Umegaki, Chikao Shimamoto, Ken-Ichi Katsu. Effect of Long-term Administration of Ammonia Water on Rat Gastric Mucosa-Combined Effect of Gastric Mucosal Protective Agents. Bulletin of the Osaka Medical College. 2007; 69-78.
8. Tsuji S, Tsujii M, Murata H, Nishida T, Komori M, Yasumaru M, Ishii S, Sasayama Y, Kawano S, Hayashi N. Helicobacter pylori eradication to prevent gastric cancer: Underlying molecular and cellular mechanisms. World J Gastroenterol. 2006; 12(11): 1671-1680.
9. Brzozowski T, Konturek PC, Konturek SJ. Mucosal irritation, adaptive cytoprotection, and adaptation to topical ammonia in the rat stomach. Scand. J. Gastroenterol. 1996; 31(9): 837-846.
10. Xiang Z, Si JM, Huang HD. Chronic gastritis rat model and role of inducing factors. World J Gastroenterol 2004; 10(21): 3212-3214.
11. Wang LJ, Chen SJ, Chen Z, Cai JT, Si JM. Morphological and pathologic changes of experimental chronic atrophic gastritis (CAG) and the regulating mechanism of protein expression in rats. Journal of Zhejiang University SCIENCE B. 2006; 7(8):634-640.
12. Si J, Zhou W, Wu J, Cao Q, Xiang Z, Jiang L, Lü W, Huang H. Establishment of animal model of chronic atrophic gastritis and a study on the factors inducing atrophy. Chinese Medical Journal 2001; 114(12): 1323-1325.
13. Zhao W, Zhu F, Shen W, Fu A, Zheng L, Yan Z, Zhao L, Fu G. Protective effects of DIDS against ethanol-induced gastric mucosal injury in rats. Acta Biochim Biophys Sin (2009): 301–308.
2. Ganchimeg U, Angarmurun D, Davaalham D. The current situation of the non-communicable disease in Mongolia. Mongolian journal of health sciences 2010; 1:7 .
3. Tumurbaatar N: Hot-Natured Disorders in Traditional Mongolian Medicine. 1998, Eruul enkh press, Ulaanbaatar
4. Manag rinchin junai: Traditional Medical source book. 1978, People's Republic of China: “Inner Mongolian medical treasurers†printing house, Ulaanbaatar
5. Ligaa U, Davaasuren B, Ninjil N: Mongolian Medicinal Plants Using in Western and Eastern Medicine. 2005, JKC printing, Ulaanbaatar
6. Myagmar BE, Aniya Y: Free radical scavenging action of medicinal herbs from Mongolia. Phytomedicine. 2000, 7: 221-9. 10.1016/S0944-7113(00)80007-0.
7. Takao Noguchi, Eiji Umegaki, Chikao Shimamoto, Ken-Ichi Katsu. Effect of Long-term Administration of Ammonia Water on Rat Gastric Mucosa-Combined Effect of Gastric Mucosal Protective Agents. Bulletin of the Osaka Medical College. 2007; 69-78.
8. Tsuji S, Tsujii M, Murata H, Nishida T, Komori M, Yasumaru M, Ishii S, Sasayama Y, Kawano S, Hayashi N. Helicobacter pylori eradication to prevent gastric cancer: Underlying molecular and cellular mechanisms. World J Gastroenterol. 2006; 12(11): 1671-1680.
9. Brzozowski T, Konturek PC, Konturek SJ. Mucosal irritation, adaptive cytoprotection, and adaptation to topical ammonia in the rat stomach. Scand. J. Gastroenterol. 1996; 31(9): 837-846.
10. Xiang Z, Si JM, Huang HD. Chronic gastritis rat model and role of inducing factors. World J Gastroenterol 2004; 10(21): 3212-3214.
11. Wang LJ, Chen SJ, Chen Z, Cai JT, Si JM. Morphological and pathologic changes of experimental chronic atrophic gastritis (CAG) and the regulating mechanism of protein expression in rats. Journal of Zhejiang University SCIENCE B. 2006; 7(8):634-640.
12. Si J, Zhou W, Wu J, Cao Q, Xiang Z, Jiang L, Lü W, Huang H. Establishment of animal model of chronic atrophic gastritis and a study on the factors inducing atrophy. Chinese Medical Journal 2001; 114(12): 1323-1325.
13. Zhao W, Zhu F, Shen W, Fu A, Zheng L, Yan Z, Zhao L, Fu G. Protective effects of DIDS against ethanol-induced gastric mucosal injury in rats. Acta Biochim Biophys Sin (2009): 301–308.
Published
2018-01-23
How to Cite
DUNGUBAT, Erdenetsogt et al.
Protective Effect of Anar-5 Herbal Treatment on Experimental Chronic Atrophic Gastritis in Wistar Rats.
Diagnostic Pathology, [S.l.], v. 4, n. 1, jan. 2018.
ISSN 2364-4893.
Available at: <https://www.diagnosticpathology.eu/content/index.php/dpath/article/view/258>. Date accessed: 21 sep. 2023.
doi: https://doi.org/10.17629/www.diagnosticpathology.eu-2018-4:258.
Issue
Section
Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
4. In case of virtual slide publication the authors agree to copy the article in a structural modified version to the journal's VS archive.
